.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC17_Tildrakizumab.Tildrakizumab

Information

Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. It is approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Pharmacokinetics

Pharmacokinetic parameters in adult patients with moderate-to-severe plaque psoriasis. Data from population PK models include both sexes, typical adult age range.

References

1. Jauslin, P, et al., & Kerbusch, T (2019). Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis. Clinical pharmacokinetics 58(8) 1059–1068. DOI:10.1007/s40262-019-00743-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30915660

2. Zandvliet, A, et al., & Khalilieh, S (2015). Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects. International journal of clinical pharmacology and therapeutics 53(2) 139–146. DOI:10.5414/CP202176 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25546162

3. Kerbusch, T, et al., & Wenning, L (2020). Exposure-response characterisation of tildrakizumab in chronic plaque psoriasis: Pooled analysis of 3 randomised controlled trials. British journal of clinical pharmacology 86(9) 1795–1806. DOI:10.1111/bcp.14280 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32162721

Revisions

• 06/2025 initial generated model